Nanobiotix receives Investment Bank Analyst Rating Update
- Investing.com
Pro
- English (USA)
- English (UK)
- English (Canada)
- English (Australia)
- English (South Africa)
- English (Philippines)
- English (Nigeria)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Polski
- Português (Portugal)
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
Nanobiotix (NANOB)
The Nanobiotix share price today is 30.16, view EPA NANOB stock exchange data. Track the latest Nanobiotix share price with real-time updates on NANOB stock performance including market cap, day range, 52-week range and dividend yield. Access NANOB charts, earnings dates and analyst estimates to support your investment decisions.
30.16
-0.96(-3.08%)
Closed·
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
30.16
31.76
52 wk Range
8.54
47.66
Earnings results expected in 14 days
1/2
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
30.1631.76
52 wk Range
8.5447.66
Key Statistics
Edit
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
NANOB Scorecard
Company’s Health
Assesses a company's financial position by analysing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceTechnical Analysis
Strong Sell
Analysts Sentiment
Strong Buy
Price Target
52.20
Upside
+73.08%
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
High return over the last year
Nanobiotix receives Investment Bank Analyst Rating Update- Investing.com
Pro
Nanobiotix receives Investment Bank Analyst Rating Update- Investing.com
Pro
Nanobiotix receives Investment Bank Analyst Rating Update- Investing.com
Pro
- Nanobiotix receives Investment Bank Analyst Rating Update
- Investing.com
Pro - Nanobiotix receives Investment Bank Analyst Rating Update
- Investing.com
Pro - Nanobiotix receives Investment Bank Analyst Rating Update
- Investing.com
Pro 
Nanobiotix receives Investment Bank Analyst Rating Update- Investing.com
Pro
Technical Analysis
Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Sell
Technical Indicators
Sell
Moving Averages
Strong Sell
Analyst Ratings
5 Buy
0 Hold
0 Sell
Ratings:
5 analysts
Overall Consensus
Strong Buy
Analysts 12-Month Price Target:
Average 52.20
(+73.08% Upside)
Earnings
Latest Release
29-05-2026
EPS / Forecast
-- / --
Revenue / Forecast
-- / --
Compare NANOB to Peers and Sector
Metrics to compare | NANOB | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipNANOBPeersSector | |
|---|---|---|---|---|
P/E Ratio | −64.0x | −2.7x | −0.4x | |
PEG Ratio | −1.02 | −0.01 | 0.00 | |
Price/Book | −18.1x | 0.9x | 2.6x | |
Price / LTM Sales | 47.0x | 17.0x | 3.0x | |
Upside (Analyst Target) | 78.8% | 180.9% | 56.0% | |
Fair Value Upside | Unlock | 13.1% | 8.7% | Unlock |
Nanobiotix S.A. operates as a clinical-stage biotechnology that focuses on developing product candidates for the treatment of cancer and other unmet medical needs. Its lead product candidate is NBTXR3, a sterile aqueous suspension of crystalline hafnium oxide nanoparticles used for the treatment of soft tissue sarcoma, head and neck, liver, prostate, pancreatic, esophageal, rectal, and non-small cell lung cancer. The company has a partnership with Lian Oncology Limited to develop and commercialize NBTXR3 in China, South Korea, Singapore, and Thailand. Nanobiotix S.A. was incorporated in 2003 and is based in Paris, France.
Ownership
Ownership Overview
Top Holders
FAQ
What Is the Nanobiotix (NANOB) Share Price Today?
The Nanobiotix share price today is 30.16.
What is the current Nanobiotix (NANOB) share price and day range?
As of 16-09-2026, the Nanobiotix share price is 30.16, with a previous close of 30.16. The share price has ranged from 30.16 to 31.76 today, while the 52-week range spans from 8.54 to 47.66.
What Is the Nanobiotix Market Cap?
As of today, Nanobiotix market cap is 1.53B.
What Is the Nanobiotix (NANOB) Share Price Target?
The average 12-month share price target for Nanobiotix is 52.20, with a high estimate of 60 and a low estimate of 40. 5 analysts recommend buying, while 0 suggest selling, with an overall rating of Strong Buy and +73.08% Upside potential.
What Is Nanobiotix's Earnings Per Share (TTM)?
The Nanobiotix EPS (TTM) is -0.50.
When Is the Next Nanobiotix Earnings Date?
Nanobiotix will release its next earnings report on 30-09-2026.
From a Technical Analysis Perspective, Is NANOB a Buy or Sell?
Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Sell.
What Stock Exchange Does Nanobiotix Trade On?
Nanobiotix is listed and trades on the Paris Stock Exchange.
What Is the Stock Symbol for Nanobiotix?
The stock symbol for Nanobiotix is "NANOB."
How Many Times Has Nanobiotix Stock Split?
Nanobiotix has split 1 times.
How Many Employees Does Nanobiotix Have?
Nanobiotix has 100 employees.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.